Cargando…
Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
Interim results from the two‐cohort, phase 2 KEYNOTE‐100 study (NCT02674061) of 376 patients with previously treated advanced recurrent ovarian cancer (ROC) showed that pembrolizumab monotherapy was associated with an objective response rate (ORR) of 8.0% (95% CI, 5.4‐11.2). We present outcomes for...
Autores principales: | Nishio, Shin, Matsumoto, Koji, Takehara, Kazuhiro, Kawamura, Naoki, Hasegawa, Kosei, Takeshima, Nobuhiro, Aoki, Daisuke, Kamiura, Shoji, Arakawa, Atsushi, Kondo, Eiji, Hirakawa, Tomoko, Yamamoto, Keiko, Aoki, Masayuki, Stein, Karen, Keefe, Stephen, Fujiwara, Keiichi, Ushijima, Kimio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156846/ https://www.ncbi.nlm.nih.gov/pubmed/32012411 http://dx.doi.org/10.1111/cas.14340 |
Ejemplares similares
-
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826
por: Nishio, Shin, et al.
Publicado: (2022) -
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775
por: Yonemori, Kan, et al.
Publicado: (2022) -
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
por: Takahashi, Shunji, et al.
Publicado: (2022) -
Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181
por: Muro, Kei, et al.
Publicado: (2021) -
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)